The screening and use of inhibitors targeting the enzymatic activity of DCTPP1 will enable a more in‐depth exploration of its role in cisplatin resistance in ovarian cancer (OC) and the potential of it serving as a cisplatin treatment enhancer. Here, DCTPP1 is linked to ovarian cancer.